University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

Br J Haematol. 2018 Apr;181(2):264-267. doi: 10.1111/bjh.14544. Epub 2017 Apr 17.
No abstract available

Keywords: MEK inhibition; novel therapies; relapsed/refractory DLBCL; selumetinib.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzimidazoles / administration & dosage*
  • Benzimidazoles / adverse effects
  • Chicago
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Middle Aged
  • Survival Rate

Substances

  • AZD 6244
  • Benzimidazoles